Comprehensive Investigation of Natural Ligands as Inhibitors of β Secretase to Identify Alzheimer's Disease Therapeutics

被引:0
作者
Kushwah, Shikha [1 ]
Mani, Ashutosh [1 ]
机构
[1] Motilal Nehru Natl Inst Technol Allahabad, Dept Biotechnol, Prayagraj 211004, India
关键词
Alzheimer's disease; BACE1; amyloid-beta hypothesis; molecular docking; MD (molecular dynamics) simulation; herbal compounds; AMYLOID HYPOTHESIS; BACE1; PATHOGENESIS; PREDICTIONS; CURCUMIN; DOCKING;
D O I
10.2174/0115672050323622240705043337
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Alzheimer's disease (AD) is an alarmingly prevalent worldwide neurological disorder that affects millions of people and has severe effects on cognitive functions. The amyloid hypothesis, which links AD to A beta (amyloid beta) plaque aggregation, is a well-acknowledged theory. The beta-secretase (BACE1) is the main cause of A beta production, which makes it a possible target for therapy. FDA-approved therapies for AD do exist, but none of them explicitly target BACE1, and their effectiveness is constrained and accompanied by adverse effects.Materials and Methods We determined the essential chemical components of medicinal herbs by conducting a thorough literature research for BACE1. Computational methods like molecular docking, ADMET (Absorption, distribution, metabolism, excretion, toxicity) screening, molecular dynamic simulations, and MMPBSA analysis were performed in order to identify the most promising ligands for beta-secretase.Results The results suggested that withasomniferol, tinosporide, and curcumin had better binding affinity with BACE1, suggesting their potential as therapeutic candidates against Alzheimer's disease.Conclusion Herbal therapeutics have immense applications in the treatment of chronic diseases like Alzheimer's disease, and there is an urgent need to assess their efficacy as therapeutics.
引用
收藏
页码:667 / 678
页数:12
相关论文
共 50 条
  • [41] Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics
    Recanatini, M
    Valenti, P
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (25) : 3157 - 3166
  • [42] Inhibition and modulation of γ-secretase for Alzheimer's disease
    Wolfe, Michael S.
    NEUROTHERAPEUTICS, 2008, 5 (03) : 391 - 398
  • [43] β-secretase as a target for the treatment of Alzheimer's disease
    Citron, M
    JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 70 (03) : 373 - 379
  • [44] Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer's disease
    Mojarad-Jabali, Solmaz
    Roh, Kyung-Ho
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2025, 669
  • [45] β-secretase as a therapeutic target for Alzheimer's disease
    Ghosh, Arun K.
    Gemma, Sandra
    Tang, Jordan
    NEUROTHERAPEUTICS, 2008, 5 (03) : 399 - 408
  • [46] β-Secretase as a therapeutic target for Alzheimer’s disease
    Arun K. Ghosh
    Sandra Gemma
    Jordan Tang
    Neurotherapeutics, 2008, 5 : 399 - 408
  • [47] Navigating the GSK-3βinhibitors β inhibitors as versatile multi-target drug ligands in Alzheimer's ' s disease intervention - A comprehensive review
    Joshi, Nachiket Jitendra
    Reddy, Alavala Raja Sekhar
    RESULTS IN CHEMISTRY, 2024, 7
  • [48] Emerging Therapeutics for Alzheimer's Disease
    Chiang, Karen
    Koo, Edward H.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54, 2014, 54 : 381 - 405
  • [49] γ-Secretase Inhibitors Selected by Molecular Docking, to Develop a New Drug Against Alzheimer's Disease
    Trasvina-Arenas, Carlos Humberto
    Medina, Luis Alejandro Ayala
    Vique-Sanchez, Jose Luis
    REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2023, 12 (02): : 340 - 349
  • [50] Update on Alzheimer's Disease Therapeutics
    Rafii, Michael S.
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (02) : 110 - 118